Incyte's targeted therapy shows durable responses in pancreatic cancer patients
Incyte reported that its targeted drug, combined with chemotherapy, produced lasting tumor shrinkage in some pancreatic cancer patients, prompting a move to late-stage trials.
The biotech firm Incyte announced that a targeted agent used alongside standard chemotherapy achieved sustained tumor responses in a subset of pancreatic cancer cases. The data support the company's decision to advance the regimen into a phase III study. This follows the recent approval of Revolution Medicines' Rasonque, which demonstrated survival benefits by hitting RAS mutations. Several firms, including Revolution Medicines, Verastem and China's Hengrui, are now pursuing next-generation RAS-focused drugs to improve outcomes further.
Why it matters
New targeted therapies could improve survival for patients with hard-to-treat pancreatic cancer.
In this story
